Title: | Guidelines for clinical application of mifepristone |
Edition: | Original |
Classification: | Standard guideline |
Field: | Others |
Countries and regions: | China |
Guidelines users: | Clinicians, pharmacists, nurses and other stakeholders. |
Evidence classification method: | The guideline will use the Grades of Recommendations Assessment, Development and Evaluation (GRADE) to rate the quality of evidence and to grade the strength of recommendations. |
Development unit: | China Medical Education Association, Beijing Association of Holistic Integrative Medicine. |
Registration time: | 2023-11-17 |
Registration number: | PREPARE-2023CN916 |
Purpose of the guideline: | A lot of medication risks related to mifepristone therapy still remain to be identified and standardized. This project aims to establish an evidenced-based practice guidelines for clinical application of mifepristone. |
Latest registration